The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.
May 13th 2024
In case you missed any, below is a recap of every episode of OncLive On Air that aired in April 2024.
Precision Genomics Moves Toward Increased Granularity in Molecular Sequencing
March 10th 2022Kelvin P. Lee, MD, discusses the nuances of an effective molecular tumor board, explains the practical application of precision oncology genomics, and highlights the pathways that have the potential to change the treatment landscape for precision oncology.
European Approval Sought for Ivosidenib in IDH1-Mutated AML and Cholangiocarcinoma
A marketing authorization application has been submitted to the European Medicines Agency for 2 indications of ivosidenib: in combination with azacitidine in the frontline treatment of patients with IDH1-mutated acute myeloid leukemia who are not candidates for intensive chemotherapy and in previously treated patients with locally advanced or metastatic IDH1-mutated cholangiocarcinoma.
Serious Concerns Cloud Potential Benefit of Liquid Biopsy in Cancer Screening
February 3rd 2022Maurie Markman, MD, explains the concerns surrounding liquid biopsies in cancer screening, and why regulatory agencies should be cautious and not approve any proposed molecularly based cancer diagnostic screening strategy until the tool is shown to effect cancer-specific survival compared with a control population not undergoing such testing.
Making Progress Against the Blood-Brain Barrier
January 31st 2022Primary and metastatic brain tumors present a significant therapeutic challenge, in large part because they are protected by the blood-brain barrier, a highly restrictive interface between the bloodstream and the brain that prevents most drugs from accessing the brain parenchyma.
Lorlatinib Approved in Europe for ALK+ Advanced NSCLC
The European Commission has granted a marketing authorization for lorlatinib for use as a single agent in the treatment of adult patients with ALK-positive advanced non–small cell lung cancer who did not receive a prior ALK inhibitor.
Targeting CD166 Represents a New Avenue of Attack for Breast Cancer
January 12th 2022High expression of activated leukocyte cell adhesion molecule, also known as CD166, occurs in approximately 50% of patients with triple-negative breast cancer and up to 80% of patients with estrogen receptor– positive, HER2-negative breast cancer.
Aggarwal Shines a Light on Precision Medicine in Lung, Breast, Ovarian, and GI Cancers
January 6th 2022Molecular testing is an established and essential precursor to treatment for patients with non–small cell lung cancer based on the volume of actionable targets, such as EGFR and KRAS G12C mutations, as well as PD-L1 status.
FDA Greenlights Companion Diagnostic for BRAF Inhibitors in Melanoma
The FDA has approved FoundationOne CDx for use as a companion diagnostic for 2 groups of current a future regulatory-approved treatments in melanoma, including single-agent BRAF inhibitors targeting BRAF V600E mutations and BRAF/MEK combination regimens targeting BRAF V600E or V600K mutations.
FDA Grants Partial Recognition to Memorial Sloan Kettering’s OncoKB Database
The Food and Drug Administration has granted recognition to a partial listing of the Oncology Knowledge Base, a comprehensive precision oncology knowledge databased developed by investigators and physicians at Memorial Sloan Kettering Cancer Center.
Genomically-Guided Radiation Dosing Model Shows Promise in Various Cancer Types
Radiation oncologists Jacob Scott, MD, DPhil, and Javier Torres-Roca, MD, discuss the benefits of using GARD in a pooled pan-cancer analysis and why there is a call to action to integrate GARD-based radiotherapy dosing in oncology.
Genomic Testing Cooperative Seeks to Increase Accessibility to Genomic Profiling Across Cancers
November 2nd 2021Maher Albitar, MD, discusses the unmet needs with genomic testing that served as the impetus to start GTC, the process of becoming a partner with the organization, and the importance of genomic profiling for all patients with cancer.
FDA Approves Companion Diagnostic for Adjuvant Atezolizumab in Stage II to IIIA NSCLC
The FDA has approved the VENTANA PD-L1 assay to assist in identifying which adult patients with stage II to IIIA non–small cell lung cancer whose tumors have PD-L1 expression on 1% or more of tumor cells are eligible to receive adjuvant atezolizumab following surgery and platinum-based chemotherapy.
Addressing AYA Cancer Requires a Tailored Approach to Practice
October 8th 2021Investigators have expanded the scientific understanding of cancer in the adolescent young adult patient population over the past decade. However, unmet needs remain in establishing treatment standards, addressing unique survivorship challenges, and providing a framework for patients to reference as they navigate their cancer journey.